In recent years, advances in genetic testing have revolutionized our understanding of cancer risk, enabling oncologists to tailor treatments and preventive strategies according to inherited genetic variants. However, a critical gap remains in translating this knowledge beyond the individual patient to their family members who may harbor the same genetic risks. Addressing this challenge, researchers at the University of Michigan Health Rogel Cancer Center have innovated an interactive digital platform named Genetic Information and Family Testing (GIFT), designed to facilitate the dissemination of genetic risk information within families. This breakthrough represents a significant leap towards personalized, cascade genetic education and testing, with the potential to transform cancer prevention paradigms.
Cancer patients who discover they carry pathogenic germline variants often grapple not only with the implications for their own health but also with the daunting responsibility of communicating these findings to relatives who might share their elevated risk. Traditional clinical workflows typically focus on the diagnosed patient, leaving relatives unmonitored and uninformed despite their potential susceptibility. This disjunction poses a critical public health lacuna: without effective outreach and counseling, families cannot make informed decisions about surveillance or preventive interventions, potentially missing the opportunity to avert future cancer cases.
The GIFT platform was meticulously engineered to bridge this communication divide by offering a comprehensive, web-based intervention. It combines educational modules elucidating the genetic underpinnings of cancer risk with decision support mechanisms that empower patients to comfortably share test results with family members. Beyond patient education, GIFT uniquely provides a secure portal through which patients can invite first- and second-degree relatives to engage with tailored content regarding their own genetic risk, alongside tools that guide them through the decision-making process about whether to pursue genetic testing.
To evaluate the efficacy of this intervention, a cluster randomized trial enrolled 414 cancer survivors diagnosed between 2018 and 2019, all confirmed carriers of pathogenic variants known to increase cancer risk. Participants were randomized across two variables: the mode of intervention delivery—online only versus facilitated by a human navigator—and the cost of genetic testing offered to relatives—either free or at a $50 fee. These parameters assessed not only the uptake of the platform but also the impact of human interaction and financial barriers on engagement rates.
The trial’s outcomes yielded insightful observations. Approximately 20% of patients utilized the platform to invite relatives, and among those relatives, roughly one-third enrolled in the program voluntarily. Strikingly, an overwhelming 90% of enrolled relatives proceeded to order genetic testing, underscoring the latent demand and readiness within families when appropriately supported. Contrary to expectations, the presence of a human navigator did not significantly augment enrollment or testing rates, affirming the potential sufficiency of a well-designed, self-directed online tool in facilitating cascade testing.
Cost analysis revealed a more nuanced dynamic. Relatives offered free genetic testing were twice as likely to complete testing compared to those facing a $50 fee, highlighting that financial incentives substantially influence testing uptake. Yet, despite the increase, overall testing numbers remained modest, pointing to persistent barriers beyond economic factors—possibly including psychological readiness or lack of awareness—that require further exploration and targeted strategies.
Steven J. Katz, M.D., M.P.H., the principal investigator and a prominent professor at the Rogel Cancer Center, emphasized the transformative promise of the GIFT platform. He noted that this web-based intervention could serve as a scalable and cost-efficient blueprint for integrating cascade genetic education and testing into routine oncology care. By empowering patients to take active roles in their family’s health communication, the tool fosters a proactive network effect that could ultimately reduce cancer incidence through early detection and prevention.
In parallel, complementary research published in JCO Oncology Practice investigated how cancer patients engage with clinicians and family members when discussing genetic test results. This study, involving nearly 1,800 women with breast, ovarian, or uterine cancer, shed light on the communication landscape surrounding hereditary cancer risk. While a significant majority engaged with genetic counselors and acknowledged encouragement to inform relatives, only a minority received concrete advice on how to navigate these sensitive conversations, and even fewer instances involved counselors directly liaising with family members. This gap highlights the “big unmet need” articulated by Allison Kurian, M.D., M.Sc., from Stanford University, and underscores the necessity of formalized family referral services within clinical practices.
Acknowledging these challenges, the research team is advancing a second-generation iteration of the GIFT platform, integrating an artificial intelligence (AI) assistant aimed at personalizing genetic risk information based on individual family dynamics and enhancing communication efficacy. By tailoring messages and resource recommendations, AI-driven customization promises to overcome psychological and informational barriers, fostering more meaningful and sustained family engagement.
Lawrence C. An, M.D., co-director of Rogel’s Center for Health Communications Research, underscored the user-friendly nature of the current GIFT platform. Participants reported ease of use and autonomy in navigating the educational materials and testing procedures without requiring assistance from human navigators. This intuitive design exemplifies how emerging digital communication technologies can effectively personalize patient outreach, break down longstanding bottlenecks in cascade testing, and ultimately narrow disparities in hereditary cancer risk management.
Looking ahead, the increasing adoption of germline genetic testing—projected to exceed 250,000 cancer patients yearly—magnifies the imperative to refine strategies for family engagement. As the compendium of recognized pathogenic variants, now encompassing over 40 cancer-associated genes, continues to expand, the healthcare system must equip itself with scalable, evidence-based tools like GIFT to ensure that genetic insights translate into actionable risk mitigation for entire families.
Successful cascade genetic testing not only clarifies individual and familial cancer risk landscapes but also empowers relatives to make informed decisions regarding enhanced surveillance or prophylactic interventions that could drastically alter disease trajectories. Although complex familial communication patterns and psychological factors present formidable barriers, digital interventions that are accessible, cost-effective, and patient-centered offer promising solutions.
The GIFT study represents a pioneering leap toward closing the loop in hereditary cancer risk management. By harnessing the confluence of genetic science, health communication, and digital technology, it paves the way for a future where inherited cancer risk is managed collaboratively within families, reducing preventable cancers and improving outcomes on a population scale.
Subject of Research: People
Article Title: Results From the Genetic Information and Family Testing (GIFT) Study: A Cluster Randomized Trial
News Publication Date: 24-Mar-2026
Web References:
References:
“Results From the Genetic Information and Family Testing (GIFT) Study: A Cluster Randomized Trial,” Journal of Clinical Oncology. DOI: 10.1200/JCO-25-02196
“Patient Engagement with Clinicians and Family Members About Genetic Test Results Across Risk Groups in Women with Hereditary Cancer Susceptibility,” JCO Oncology Practice. DOI: 10.1200/OP-25-00776
Image Credits: Jacob Dwyer, Michigan Medicine
Keywords: Genetic testing, Genetic counseling, Cancer, Cancer genetics
